title: Okadaic acid modulates exocytotic and transporter-dependent release of dopamine in bovine retina in vitro.
abstract: Bovine retinas were isolated for the study of the modulation of exocytotic and transporter-dependent release of dopamine (DA) in vitro. Endogenous DA was measured in the medium using HPLC with electrochemical detection under successive incubations with transfers in fresh medium every 30 min. As expected, potassium caused a calcium-dependent exocytotic liberation of DA. Amphetamine or tyramine induced a calcium-independent release by reversing DA transport across the plasma membrane. Okadaic acid, a specific inhibitor of phosphatases 1 and 2A, induced a slight but significant DA release in the absence of calcium. Furthermore, the toxin increased potassium-, amphetamine- or tyramine-induced DA release independently of extracellular calcium. In addition, okadaic acid completely annulled the ability of a calcium-free extracellular environment to inhibit the potassium-induced DA release. Finally, the toxin prevented the time-dependent decline in the efficacies of amphetamine or tyramine to release DA. In agreement with proposed schemes described for rat striatum, the results of the present study confirmed the existence of distinct release modes of DA in bovine retina. The results obtained with okadaic acid suggest that phosphatase 1 and/or phosphatase 2A constitute part of a direct or indirect mechanism to inhibit both exocytotic and transporter-dependent DA release.
authors.affiliation: Département de Pharmacologie, Centre Médical Universitaire, Genève, Switzerland.
authors.forename: O
authors.initials: O
authors.lastname: Bugnon
authors.forename: S
authors.initials: S
authors.lastname: Ofori
authors.forename: M
authors.initials: M
authors.lastname: Schorderet
mesh_terms: D000818:Animals; D002118:Calcium / Q000502:physiology; D002352:Carrier Proteins / Q000187:drug effects*; D002417:Cattle; D002851:Chromatography, High Pressure Liquid; D046508:Culture Techniques; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D004988:Ethers, Cyclic / Q000494:pharmacology*; D005089:Exocytosis / Q000187:drug effects*; D019319:Okadaic Acid; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors*; D011188:Potassium / Q000494:pharmacology; D054645:Protein Phosphatase 1; D054648:Protein Phosphatase 2; D012160:Retina / Q000187:drug effects* / Q000502:physiology; D014439:Tyramine / Q000494:pharmacology
chemical_list: D002352:Carrier Proteins; D004988:Ethers, Cyclic; D019319:Okadaic Acid; D010749:Phosphoprotein Phosphatases; D054645:Protein Phosphatase 1; D054648:Protein Phosphatase 2; D011188:Potassium; D002118:Calcium; D003913:Dextroamphetamine; D004298:Dopamine; D014439:Tyramine